Publications
246
Citations
2,351
Est. group size
~58
Recurring co-author estimate
Active years
33
Publishing since 1994
Typically publishes in teams of ~13 · 14% small-team papers (≤3 authors) · across 14 venues
- Abstract CT109: A phase 0/1 study of PRMT5 inhibitor BMS-986504 in recurrent glioblastoma participants with MTAP deletion
Cancer Research · 2026
- Abstract LB124: Patient-derived organoid-immune cell co-cultures and spatial biology support a CD44v9 cancer stem cell-directed therapeutic strategy for adamantinomatous craniopharyngioma
Cancer Research · 2026
- Sources matter: Learning to evaluate large language models for oncology treatment plans and changes observed by anchoring models to an oncology-specific database.
Journal of Clinical Oncology · 2026
- Gliofocus: A global, open-label, randomized phase 3 study comparing niraparib with temozolomide in newly diagnosed MGMT-unmethylated glioblastoma.
Journal of Clinical Oncology · 2026
- Single-nucleus transcriptomics, pharmacokinetics, and pharmacodynamics of CDK4/6 and mTOR inhibition in a Phase 0/1 trial of recurrent high-grade glioma
Neuro-Oncology · 2025
- Resolution of Refractory Status Epilepticus With Ketamine Without Intubation in a Patient With Stroke‐Like Migraine Attacks After Radiation Therapy (SMART) Syndrome
Case Reports in Neurological Medicine · 2025
- Robust Cluster Prediction Across Data Types Validates Association of Sex and Therapy Response in GBM
Cancers · 2025
- Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: Efficacy and safety from the phase II PROSPECT study.
Journal of Clinical Oncology · 2025
- Abstract 2513: Factors influencing participant attrition in Phase 0 hybrid clinical trials for patients with high-grade glioma
Cancer Research · 2025
- A global phase 3, open-label, randomized 2-arm study comparing the clinical efficacy and safety of niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma.
Journal of Clinical Oncology · 2025
- Abstract CT023: A phase 0/1 ‘trigger’ trial of BDTX-1535 in recurrent glioblastoma (GBM) patients with EGFR alterations or fusions
Cancer Research · 2025
- 88 | TIRABRUTINIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE II PROSPECT STUDY
Hematological Oncology · 2025
- DSAI-05 FINE-TUNING LARGE LANGUAGE MODELS USING NCCN GUIDELINES TO STREAMLINE PHYSICIAN ASSESSMENT AND PLANS FOR CNS METASTATIC CANCER: A TRIAL-IN-PROGRESS
Neuro-Oncology Advances · 2025
- P12.27.B A PHASE 0/1 STUDY OF PRMT5 INHIBITOR BMS-986504 IN RECURRENT GLIOBLASTOMA PARTICIPANTS WITH MTAP DELETED TUMORS.
Neuro-Oncology · 2025
- P12.29.B PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL DATA UPDATE FROM PHASE 0/1 TRIAL FOR BDTX-1535 IN RECURRENT GLIOBLASTOMA PATIENTS WITH EGFR ALTERATIONS.
Neuro-Oncology · 2025
- Neuro-Oncology×50
- Journal of Clinical Oncology×13
- Cancer Research×9
- Neuro-Oncology Advances×8
- International Journal of Radiation Oncology*Biology*Physics×6
- Michelle M. Kim
Medicine · University of Michigan
- Ryo Kurokawa
Medicine · University of Michigan
- Rodrigo T. Cartaxo
Medicine · University of Michigan
- Heidi Baum
Medicine · University of Michigan
- Akash Deogharkar
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile